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Abstract The membrane-bound gpl30 glycoprotein acts as an 
affinity converting and signal transducing receptor (R) for 
interleukin-6 and several other cytokines. In this work, we RT-
PCR amplified gpl30 cDNA using primers flanking the sequence 
encoding the transmembrane domain of gpl30. We observed in 
blood mononuclear cells, in addition to the expected 333-bp 
length fragment, a second major band of 418 bp. Sequencing of 
the 418-bp fragment and its genomic counterpart showed a new 
85-bp exon located in the sequence encoding the extracellular 
region of the gpl30 protein. This exon is most likely due to 
alternative splicing and leads to a frame-shift resulting in a stop-
codon 1 bp before the transmembrane coding region. Corre-
spondingly, supernatants from Chinese hamster ovary cells 
transfected with this cDNA contained 4-5 times more soluble 
(s) gpl30 than supernatants from cells transfected with a cDNA 
encoding the membrane-bound gpl30 protein. Both gpl30 and 
alternatively spliced sgpl30 were also transcribed by the 
myeloma cell lines XG-1, XG-2, XG-4, XG-4CNTF XG-6, 
XG-7, XG-9, XG-10, U266 and RPMI 8226. However, XG-4A 
cells derived from XG-4 cells, but growing independently of 
exogenous IL-6, did not transcribe sgpl30 mRNA. A possible 
interference with intracrine stimulatory factors by alternatively 
spliced sgpl30 needs to be further investigated. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The membrane bound glycoprotein gpl30 was initially 
demonstrated to be a high-affinity converter and signal trans-
ducer for IL-6 [1]. Later, it was also shown to be part of the 
receptor complexes involved in the binding of leukemia inhib-
itory factor (LIF) [2,3], oncostatin M (OSM) [3,4], IL-11 [5], 
ciliary neurotrophic factor (CNTF) [2], and cardiotrophin-1 
(CT-1) [6]. This would explain why these cytokines share sev-
eral effects [5-7]. For some of the cytokines in this group, a 
specific oc-chain receptor component has been identified [8-
11]. Thus, the IL-6 receptor (R) complex consists of at least 
two glycoproteins, the a component (gp80/IL-6R) and the (3 
component (gpl30) [1]. gp l30 does not by itself bind IL-6 but 
associates with the complex of IL-6 and gp80/IL-6R. Both 
gp80/IL-6R and gpl30 belong to the hematopoietic growth 
factor family of cytokines [12,13] 
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Soluble (s) forms of many cytokine receptors have been 
described (reviewed in [14,15]). For example, sgpl30 is found 
in normal human serum at concentrations of 390 ± 72 ng/ml. 
The serum sgpl30 consists of two different forms with MT of 
a round 90 and 110 k D a [16]. 
Whereas the sIL-6R, the s C N T F R and the s I L - H R have 
been shown to have a ligand agonistic effect in several in vitro 
systems [17-19], most soluble cytokine receptors, among these 
sgpl30, act as antagonists to their respective ligands [16]. 
However, soluble receptor function in cytokine transport or 
protection against degradation have also been suggested [15]. 
Soluble cytokine receptors are generated by either proteo-
lytic cleavage (shedding) of their membrane-bound counter-
parts, or by alternative m R N A splicing, resulting in a tran-
script encoding a soluble receptor. A combination of these 
two mechanisms has been described for sIL-6R generation 
[20,21]. 
Investigating a cell line transfected with the c D N A encod-
ing the membrane-bound gpl30, Miillberg et al. reported that 
sgpl30 is generated by a shedding mechanism, but the extent 
of gp l30 shedding was much lower than that of gp80/IL-6R 
[22]. Here, we report the identification and cloning of a gpl30 
generated by alternative splicing of a new 85-bp exon. In 
addition we demonstrate that this m R N A encodes a sgpl30 
molecule when transfected into Chinese hamster ovary (CHO-
K l ) cells. 
2. Materials and methods 
2.1. Cells 
Peripheral blood mononuclear cells were isolated from normal in-
dividuals using Lymphoprep (Nycomed Pharma, Oslo, Norway) ac-
cording to the manufacturer's instructions. Multiple myeloma cell 
lines XG-1, XG-2, XG-4, XG-4CNTF, XG-4A, XG-6, XG-7, XG-9, 
XG-10, U266 and RPMI 8226 were grown as previously described 
[23,24]. By growing XG-4CNTF cells in decreasing concentrations 
of recombinant (r) human (h) IL-6, a cell line (XG-4A) growing in-
dependently of exogenously added IL-6 was established. This cell line 
was grown in RPMI 1640, supplemented with 10% fetal calf serum 
(FCS) (Gibco BRL, Roskilde, Denmark). CHO-K1 cells were grown 
in RPMI 1640+10% (FCS) 
2.2. Primers 
Primers were selected for PCR analysis using the gpl30 sequence 
submitted to Genbank by Hibi et al. (GenBank accession No. 
M57230) [12] (Fig. 1). Primers were purchased from Pharmacia Bio-
tech (Allerod, Denmark). 
2.3. RNA extraction, nuclease treatment and poly-A mRNA 
purification 
Cells, 2X107, were harvested by centrifugation in 50-ml polypro-
pylene tubes (Nunc, Roskilde, Denmark) and total RNA was ex-
tracted as described by Chomczynski et al. [25], RNA integrity was 
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investigated by running a sample on a 1% TBE gel followed by ethi-
dium bromide staining. In some experiments, the RNA was treated 
with RNAse and/or DNAse before reverse transcription. In a total 
volume of 20 ul, 10 ug total RNA was incubated with 2 ul 10XRQ1 
buffer (Promega Madison, WI, USA), 0.5 ug RNAse, (DNAse-free, 
Boehringer Mannheim, Mannheim, Germany) and/or 1 u RQ1 
DNAse, RNAse-free (Promega). After incubation for 30 min at 
37°C, samples were heated to 65"C for 10 min. Poly-A mRNA was 
purified using a Dynabeads mRNA direct kit (Dynal, Skjayen, Nor-
way). In an Eppendorf tube, 100 ul (dT)25 Dynabeads were washed in 
binding buffer (100 mM Tris-HCl, pH 8.0, 500 mM LiCl, 10 mM 
EDTA, 1% LiDS, 5 mM dithiothreitol (DTT)), and 20 ul pretreated 
RNA solution was added. After 5 min, the tube was placed in a 
magnetic particle concentrator (MPC) and the supernatant removed. 
After washing 2 times with washing buffer (10 mM Tris-HCl, pH 8.0, 
0.15 M LiCl, 1 mM EDTA) with 0.1% LiDS and once with washing 
buffer without LiDS, the poly-A mRNA was eluted in 20 ul elution 
buffer (2 mM EDTA, pH 8.0) at 65°C for 2 min. 
2.4. cDNA synthesis 
Synthesis of cDNA was carried out using Superscript II reverse 
transcriptase (RT) (Gibco BRL). After denaturation at 75°C for 
5 min and cooling to 4°C, RNA (1 ug total RNA or 5 ul poly-A 
mRNA) was incubated with 4 ul 5 X reaction buffer, 2 ul DTT (0.1 M), 
2 ul rRNasin (40 u/ul), 2 ul dNTP (10 mM), 1 ul oligo(dT)15 (50 uM), 
1 |il Superscript II RT (50 u/ul) and incubated at 42°C for 1 h fol-
lowed by 5 min at 95°C. 
2.5. PCR 
In 0.2-ml PCR tubes (Perkin Elmer, Allerod, Denmark) a master 
mix consisting of 3 ul 10 X PCR buffer II (Perkin Elmer), 9.5 ul H 2 0 , 
1 ul dNTP (10 mM of each), 5 ul upper primer (10 uM), and 5 ul of 
lower primer (10 uM). An Ampliwax PCR gem (Perkin Elmer) was 
added and the tube heated to 75°C for 5 min. After cooling and 10 min 
incubation at room temperature, a master mix consisting of 20 ul 
H 2 0 , 10XPCR buffer II, 3 ul MgCl2, 1 ul of template cDNA and 
0.5 ul Taq polymerase (2.5 u/ul) was added. Samples were placed in a 
PTC 200 thermocycler (MJ Research, Watertown, MA, USA) and 
denatured for 4 min at 96°C. After denaturation, 35 cycles of PCR 
were run. Each cycle consisted of denaturation at 96°C, for 20 sec, 
annealing at 60°C for 30 sec, and extension at 72°C for 80 sec. After 
the last cycle, extension was performed for 5 min followed by cooling 
to 4°C. 
2.6. Southern blotting 
PCR samples were analyzed on an 1% TAE agarose gel. Amplified 
DNA was detected by ethidium bromide staining and capillary trans-
ferred to Zetaprobe blotting membranes according to the manufac-
turers instructions (Bio-Rad, Hercules, CA, USA). Membranes were 
hybridized overnight at 45°C with y-32P-ATP (Amersham, Little Chal-
font, UK) 5'-end kinase-labeled oligonucleotide probes in hybridiza-
tion solution (9XSSC, 0.015 M EDTA, 3xDenhardt's solution, 0.15 
mg/ml denatured salmon sperm DNA, 0.015% SDS). Membranes 
were washed at room temperature 6x20 min followed by 3x10 
min at 45°C in 2XSSC, 0.05% SDS. After washing, the membranes 
were exposed to radiosensitive film. 
2.7. Cloning and DNA sequencing 
PCR products were gel purified using the Wizard PCR purification 
kit (Promega) and cloned in the pCRII vector supplied in the TA-
cloning kit (Invitrogen, Leek, The Netherlands). Sequencing was done 
on a automatic DNA sequencer (ALFexpress, Pharmacia Biotech) 
using the dideoxynucleotide sequencing method using a thermoseque-
nase cycle sequencing kit (Amersham). 
2.8. Cloning and expression of the alternatively spliced sgpl30 
The TA cloned U2-L2 PCR product containing an 85-bp insertion 
was digested with EcoRI and ifa(EII and the resulting 269-bp frag-
ment was gel purified using the Wizard PCR purification kit (Pro-
mega). The XhollXbal fragment of gpl30 cDNA was excised from the 
gpl30 mammalian expression vector pRcgl0-gpl30 [26]. After gel 
purification, the XhollXbal insert was further digested with .EcoRI 
and BstElI resulting in 2 fragments of approx. 1 and 2 kb. The 3 
fragments were cloned back into the expression vector pRcglO result-
ing in pRcgl0-sgpl30. The expression vectors were transfected in 
CHO-K1 cells using the DOTAP lipofection reagent (Boehringer 
Mannheim). Five ug DNA+30 ul DOTAP reagent were transfected 
to approx. 0.5 X 106 cells in Nunc culture dishes (60 mm in diameter). 
The medium was changed after 24 h. Supernatants were harvested 24 
h later and sgpl30 concentrations measured using a sgpl30 ELISA 
with a detection limit of 80 pg/ml (R and D Systems, Oxon, UK). The 
expression of membrane-bound gpl30 by transfected CHO-K1 cells 
U1 U2 U3 U4 P1 
~fh 
L1 L2 L3 L4 
Name 
U1 
U2 
U3 
U4 
L1 
L2 
L3 
L4 
P1 
Sequence (5'-3') 
aatggaaaaagcatgacatttagaa 
aaatgaaactgctgtgaatgtggatt 
tggcagcatacacagatgaaggtgg 
gcttgagtcttgccaacgaggacctt 
aaggtcctcgttggcaagactcaag 
tgccttggaggagtgtgaggtgacca 
gccgctcctctgaatctaac 
tagctttactttataggtactgctga 
tcgtgcctgtttgcttagcattcct 
Position on qp130 cDNA* 
-94 - -70 
1689-1714 
1775-1799 
-
-
1996-2021 
2358 - 2377 
2783 - 2808 
1865-1899 
* Primer bp positions are numbered according to the gp130 sequence published by Hibi et 
al. [12]. 
Fig. 1. Primers used for gpl30 PCR amplification. The gpl30 coding region is boxed. The transmembrane coding region is shown in solid and 
the hatched section represents the new exon described in this paper. *Primer bp positions are numbered according to the gpl30 cDNA se-
quence published by Hibi et al. [12]. 
M. Diamant et al.lFEBS Letters 412 (1997) 379-384 381 
was investigated by flow cytometry, using the GPX7 anti-gpl30 anti-
body (ab), as described previously [27]. 
3. Results 
3.1. Characterization of a splice variant of the gpl30 mRNA 
cDNA was prepared from polyA+ mRNA extracted from 
BMNC. A 333-bp fragment containing the transmembrane 
coding region of the gpl30 cDNA was PCR amplified by 
use of the primer pair U2-L2 (Fig. 1). Besides the expected 
333-bp fragment, several fragments with higher MW were also 
detected (Fig. 2). The fact that all PCR products disappeared 
after RNAse treatment before RT suggests, that they were 
- 653 bp 
^-517 bp 
-453bp 
^397bp 
^ 298 bp 
B 1 2 3 4 
-0.42 kb 
-0.33 kb 
Fig. 2. A) Ethidium bromide staining of an RT-PCR run in 1% 
agarose. Normal BMNC cDNA was PCR amplified with primers 
U2 and L2. mRNA purification and cDNA synthesis were carried 
out with untreated RNA (lane 1), RNAse treated RNA (lane 2), 
DNAse treated RNA (lane 3), or with both DNAse and RNAse 
treatment (lane 4). MW markers: X DNAXEcoRI+HindlU (lane 5) 
and pBR328DNAXBg/I+pBR328 DNAXT/OTH (lane 6). B) South-
ern blot of the same gel as in A hybridized with y-32P-ATP 5'-end 
kinase-labeled PI oligonucleotide. Arrows indicate the sgpl30 PCR 
product. 
generated from different gpl30 mRNA variants. DNAse treat-
ment before RT had no effect (Fig. 2). TA-cloning and com-
plete sequencing of the most abundant of the PCR products 
with a higher MW than expected, revealed that it corresponds 
to the sequence of gpl30 mRNA with an 85-bp insertion 
located just before the transmembrane coding domain of the 
gpl30 cDNA. The predicted amino-acid sequence generated 
by this mRNA showed that the 85-bp insertion results in a 
frame-shift (Fig. 3A). The sequence following the insertion 
encodes 4 amino acids followed by a stop codon placed 1 bp 
before the sequence encoding the transmembrane part of 
gpl30, strongly suggesting that the cDNA encodes a trun-
cated soluble form of gpl30. 
Two primer pairs Ul-Ll and U4-L4, were used to PCR 
amplify the 5'- and 3'-ends, respectively, of the cDNA con-
taining the 85-bp insertion. Complete sequencing of these 
showed that, apart from the 85-bp insertion, they were iden-
tical with the gpl30 sequence published by Hibi et al. [12] (not 
shown). 
3.2. Genomic PCR 
To investigate the exon-intron junctions of the newly dis-
covered exon, the primer pairs U3-L1 and U4-L2 were used to 
PCR amplify genomic DNA isolated from normal BMNC. 
Sequence analysis of the fragments, demonstrated the pres-
ence of an intron flanking each side of the sgpl30 specific 
exon. In accordance with the known consensus sequences 
for exon-intron junctions [28], both intron sequences began 
with GT at their 5'-end and ended with AG at their 3'-end 
(Fig. 3B), 
3.3. Expression of sgpl30 mRNA in CHO-K1 cells 
The sgpl30 cDNA was cloned in the mammalian expression 
vector pRcglO containing a cytomegalovirus promoter [26]. 
This construct was transiently transfected into CHO-K1 cells. 
As controls, untransfected CHO-K1 cells, CHO-K1 cells 
transfected with pRcgl0-gpl30 or pRcglO without insert 
were used. The concentrations of sgpl30 protein in trans-
fected CHO-K1 cell supernatants were determined by an 
sgpl30 specific ELISA. As shown in Fig. 4, no sgpl30 protein 
was detected in untransfected or CHO-K1 cells transfected 
with the pRcglO vector without insert. The sgpl30 concentra-
tion in supernatants from pRcgl0-sgpl30 transfected cells was 
0.63 ng/ml, whereas pRcgl0-gpl30 transfected cell superna-
tants contained 0.14 ng/ml. 
Flow cytometry of the transfected CHO-K1 cells, using the 
GPX7 anti-gpl30 ab, showed that only cells transfected with 
pRcgl0-gpl30 expressed membrane-bound gpl30. No mem-
brane-bound gpl30 was detected on untransfected cells or 
cells transfected with pRcgl0-sgpl30 (results not shown). 
3.4. Alternative sgpl30 mRNA in MM cell lines 
To investigate if the alternative sgpl30 mRNA was ex-
pressed by MM cell lines, RNA isolated from eleven different 
MM cell lines and BMNC from three normal individuals were 
reverse transcribed. The cDNA was PCR amplified using the 
primer pair U4-L3. As shown in Fig. 5A, the expected 591-bp 
band, containing the 85-bp insertion, was amplified from all 
cDNA samples, except from the MM cell line XG-4A. Several 
other bands were also seen, both with higher and lower MW 
than the expected. All PCR amplified bands were unaffected 
by DNAse treatment of the RNA before RT, whereas pre-
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A. 
1800 1840 
ggg aag gat ggt cca gaa ttc act ttt act ace cca aag ttt gTC 
Gly Lys Asp Gly Pro Glu Phe Thr Phe Thr Thr Pro Lys Phe Val 
TCA TGG ATC CAT TAT GGC TTC TTC ACA TGG CTT GAG TCT TGC CAA 
Ser Trp lie His Tyr Gly Phe Phe Thr Trp Leu Glu Ser Cys Gin 
1841 
CGA GGA CCT TAC AGC TTA GTT GAA GAA ATT TTG CAT AAc tea agg 
Arg Gly Pro Tyr Ser Leu Val Glu Glu lie Leu His Asn Ser Arg 
1856 
aga aat tga 3' 
Arg Asn *** 
5' taccccaaagtttggtaagaaata tctgtagTCTCATGGATCCATT 
ATGGCTTCTTCACATGGCTTGAGTCTTGCCAACGAGGACCTTACAGCTTAGTTG 
AAGAAATTTTGCATAAgtaaatcaga ttttaagctcaaggagaaat 3' 
1841 1937 
New 85 bp exon 
Fig. 3. (A) cDNA and predicted amino acid sequence of sgpl30 cDNA. The new 85-bp exon nucleotide sequence is written in capital letters. 
(B) Exon/intron junctions flanking the new 85-bp exon (capital letters). Consensus GT-AG sequences are underlined. Exons are written in bold. 
(C) Schematic representation of part of the gpl30 genomic sequence. The coding regions are boxed. The hatched region represents the new 
85-bp exon and the solid section represents the transmembrane coding region. The size is not representative of the actual exon/intron length in 
bp. Bp numbering is according to Hibi et al. [12]. 
treatment with RNAse resulted in the disappearance of all 
amplified products (results not shown). 
To further investigate the levels of sgpl30 mRNA by the 
cell lines XG-4, XG-4CNTF and XG-4A, cDNA was ampli-
fied both with primers specific for both gpl30 and sgpl30 
(U2-L3) and primers specific for sgpl30 (U4-L3). Blotting 
of the PCR products followed by hybridization with a y-32P-
labeled oligonucleotide (PI) demonstrated that all three cell 
lines transcribed gpl30 mRNA, whereas sgpl30 mRNA was 
only detected in XG-4 and XG-4CNTF cells (Fig. 5B). The 
0.35 kb band seen in lanes 3, 4, 6, 7 and 13 in Fig. 5A was not 
detected by the hybridization (Fig. 5B), indicating that this 
band was unrelated to gpl30. Sequencing of the 0.35-kb band 
confirmed this and showed that it was amplified by the 5' 
primer alone. In contrast, the 1.9 and 1.4-kb bands found 
after RT-PCR of mRNA isolated from XG-4 and XG-
4CNTF were also detected by the oligonucleotide hybridiza-
tion (Fig. 5B). 
4. Discussion 
We have demonstrated the presence of an alternatively 
spliced mRNA encoding a soluble form of gpl30 of 624 aa. 
The mRNA has an 85-bp exon inserted in the part encoding 
the extracellular part of the receptor. This exon gives rise to a 
frame-shift resulting in a stop-codon, 1 bp before the begin-
ning of the transmembrane coding part of the mRNA. The 
genomic sequence of gpl30 showed that the 85-bp exon was 
flanked by introns and an intron was also found between 
cDNA bp 1937 and 1938. 
Several other soluble cytokine receptors, belonging to the 
hematopoietic growth factor superfamily of receptors, are also 
Neg. control 
pRcglO 
pRcg10-sgp130 
pRcg10-gp130 
100 200 300 400 500 600 
sgp130(pg/ml) 
Fig. 4. Soluble gpl30 in supernatants harvested from transiently 
transfected CHO-K1 cells. Cells, 0.7 X106, were transfected with 
5 Lig of each plasmid. 
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— 653 bp 
— 517 bp 
Fig. 5. A) sgpl30 RT-PCR using primer pair U4-L3 of RNA isolated from normal BMNC and MM cell lines. RNA from normal BMNC 
(lanes 1, 14 and 16), from MM cell lines XG-1 (lanes 2 and 11), XG-2 (lane 3), XG-4 (lane 4), XG-4CNTF (lane 5), XG-4A (lane 6), XG-6 
(lane 7), XG-7 (lane 8), XG-9 (lane 9), XG-10 (lane 10), U266 (lane 12), RPMI 8226 (lane 13), negative control with no RNA added in cDNA 
synthesis (lane 15). MW markers: X, DNAXEcoRl + Hindlll (lane 17) and pBR328DNAXBgll + pBR328 DNAX/finfl (lane 18). Arrow indi-
cates PCR product of the expected 591 bp. (B) Southern blot of RT-PCR products from MM cell lines. cDNA from XG-4 (lanes 1 and 2), 
XG-4CNTF (lanes 3 and 4 and XG-4A (lanes 5 and 6) was PCR amplified using the primers U2-L3 (lanes 1, 3 and 5) or U4-L3 (lanes 2, 4 
and 6). The blot was hybridized with y-32P-ATP 5'-end kinase-labeled PI oligonucleotide. 
generated by mRNA splice variants, adding an exon that 
causes protein chain termination before the transmembrane 
domain. This is the case for the soluble forms of the murine 
(m) IL-4R [29], the human IL-5R [30], the mLIFR [31], and 
the mouse and rat leptin receptor [32,33]. 
During morula to blastocyst transition, human embryos 
have been shown to produce a mRNA encoding a truncated 
gpl30, in which the cDNA sequence between bp 1840 and 
1938 is missing. This leads to a frameshift resulting in 45 
new amino acids before a stop-codon. Consequently, this 
mRNA does not encode the transmembrane and intracellular 
part of the protein [34]. This is in good accordance with our 
findings of two introns being present between gpl30 cDNA 
bp. 1840/1841 and 1937/1938. Although protein expression 
studies of this cDNA were not reported, it is predicted that 
it encodes another form of soluble gpl30. 
Using a cell line stably expressing both membrane-bound 
gpl30 and gp80/IL-6R, Miillberg et al. showed that both 
molecules were proteolytically cleaved and released as soluble 
receptor proteins. Compared to the gp80/IL-6R, the extent of 
gpl30 shedding was almost negligible, and was not stimulated 
by the phorbol ester PMA [22]. In accordance, we also found 
that CHO-K1 cells transfected with pRcgl0-gpl30 released 
sgpl30, although at a concentration 4—5 times lower than 
that of CHO-K1 cells transfected with pRcgl0-sgpl30. The 
sgpl30 thus seems to be generated both by a shedding and 
an alternative splicing mechanism. This might explain the 
presence of two different species of sgpl30 as described by 
Narazaki et al. [16]. Which mechanism of sgpl30 generation 
that is quantitatively the most important in non-transfected 
cells is not answered by the present studies. Antibodies gen-
erated against the terminal end of either form of sgpl30 
should be able to discriminate between them and provide 
the means of answering this question. 
Several cytokines using gpl30 as a signal transducer, such 
as IL-6, LIF, OM, IL-11 and CNTF, are important growth 
factors for myeloma cells [24,35,36]. In some myeloma cell 
lines, IL-6 sensitivity is augmented by the addition of sIL-
6R [27,37]. The myeloma cell responsiveness to IL-6 depends 
on the relative amounts of IL-6, sIL-6R, membrane-bound 
gp80/IL-6R and membrane-bound gpl30 [27]. RT-PCR anal-
ysis using the primer pair U4-L3, detected the alternatively 
spliced sgpl30 mRNA in both normal BMNC and 10 of 11 
different myeloma cell lines. Furthermore, this RT-PCR de-
tected 2 bands of higher MW than expected (Fig. 5). Their 
size and the disappearance of all bands after RNAse pretreat-
ment of the RNA showed that they were not due to genomic 
DNA contamination of the RNA preparations. The 1.9 and 
1.4-kb bands further hybridized to a gpl30 specific oligonu-
cleotide probe, indicating that these bands could be other 
gpl30 splice variants. This is presently being investigated. 
It has been shown that proliferation of several transformed 
cell lines is stimulated in an autocrine way, i.e. the cells pro-
duce their own growth factor(s). For instance, the myeloma 
cell lines U266 and RPMI 8226 both produce IL-6, IL-6R and 
gpl30. Levy et al. demonstrated that the cellular proliferation 
of these cell lines was not inhibited by neutralizing antibodies 
against IL-6. However, the use of antisense technology to 
specifically inhibit the expression of IL-6 inhibited cellular 
proliferation [38]. Similar results have been found in cultures 
of non-transformed human fibroblasts [39]. 
The above findings are believed to be due to the presence of 
an intracrine stimulatory mechanism, in which ligand receptor 
binding and signal induction takes place inside the cells most 
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likely in secretory granules containing bo th the growth factors 
and their receptors [40]. This, and the fact that most soluble 
receptors seem to act as inhibitors of their respective ligands 
indicates a possible functional difference of alternatively 
spliced and proteolytically cleaved soluble receptors. Soluble 
receptors generated by proteolytic cleavage of their mem-
brane-bound counter-parts would thus only function extra-
cellularly, inhibiting their paracrine or endocrine ligands. In 
contrast, alternatively spliced soluble receptors might also 
have an intracellular function inhibiting self-stimulatory ef-
fects induced by intracrine factors. This hypothesis might ex-
plain the differences in IL-6 sensitive growth and expression of 
alternatively spliced sgpl30 by the cell lines XG-4, X G -
4 C N T F and XG-4A. In contrast to XG-4 and X G - 4 C N T F , 
XG-4A cells grow independent of added IL-6 and other gpl30 
related cytokines. We hypothesize that an intracrine growth 
promoting effect of gpl30-stimulating cytokines produced by 
the three cell lines, may be inhibited by alternatively spliced 
sgpl30 in XG-4 cells and X G - 4 C N T F cells. On the other 
hand, in XG-4A cells, lacking alternatively spliced sgpl30, 
the production of intracrine gpl30 related cytokines suffices 
to stimulate cell proliferation. Experiments to substantiate this 
hypothesis are currently underway. 
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